Ayan is a translational neuroscientist with over a decade of experience in CNS drug discovery and biomarker development. He began his research career at the Vanderbilt Center for Neuroscience Drug Discovery and went on to hold key scientific roles at the Stanley Center for Psychiatric Research at the Broad Institute, Sunovion Pharmaceuticals, and most recently, Biogen.

Ayan is deeply committed to bridging the gap between preclinical research and clinical translation. His work has spanned rare neurodevelopmental, neuropsychiatric, and neurological disorders, with a strong focus on biomarkers and therapeutic strategies across modalities—including small molecules, biologics, gene therapies, and antisense oligonucleotides (ASOs). At Biogen, he served as the translational lead for multiple rare neurodevelopmental programs, driving biomarker strategy and guiding both preclinical and clinical development.

Ayan earned his PhD in neuroscience from Vanderbilt University and completed his postdoctoral training at Vanderbilt University Medical Center.

Trish holds a Masters in Public Administration from the University of South Carolina and has worked in patient advocacy and patient engagement for over 20 years, primarily leading research initiatives, public-private partnerships and patient education and support.

Trish is currently an independent consultant facilitating the development of public-private partnerships and supporting the creation and management of consortia. In this capacity, Trish supports the management of the CureSHANK Biomarkers and Outcome Measures Consortium.